Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1632
This examiner grants 64% of resolved cases
Valarie E Bertoglio is an examiner in Tech Center 1600 and Art Unit 1600 with 867 resolved cases. She has an allowance rate of 64.0 percent and a median days to allowance of 1200. These metrics provide a picture of the prosecution landscape for the 867 cases she has handled. The 1200-day median is a benchmark for the duration of applications in the 1600 tech center.
The interview lift of 30.3 percent is a significant figure compared to the 64.0 percent allowance rate. It suggests that interviews are a productive way to increase the probability of a grant. With 867 cases resolved, the 1200-day median pendency is a factor for applicants to manage. The 30.3 percent lift is an indicator that verbal communication can help resolve issues that written responses might not. Practitioners should use the 1200-day median to set expectations while utilizing the 30.3 percent lift to improve their odds.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18283675 | ADIPOSE-DERIVED HYDROGEL COMPOSITIONS AND METHODS OF USE | Final Rejection | University of Massachusetts |
| 18161546 | METHODS OF DIFFERENTIATION TO NEURONAL CELLS AND KITS THEREFOR | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 17226642 | Hematopoietic Stem and Progenitor Cell Expansion System | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 18686552 | HYDROGELS COMPRISING CELL ADHESIVE PEPTIDES AND METHODS OF USE THEREOF | Final Rejection | GEORGIA TECH RESEARCH CORPORATION |
| 19374947 | COMPOSITIONS AND METHODS FOR OBTAINING HUMAN INTESTINAL TISSUE AND RELATED USES THEREOF | Final Rejection | The Regents of the University of Michigan |
| 18635885 | USE OF ICOS-BASED CARS TO ENHANCE ANTITUMOR ACTIVITY AND CAR PERSISTENCE | Final Rejection | The Trustees of the University of Pennsylvania |
| 17909263 | Scaffold-Free Nerve Conduit | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17771723 | GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 18267980 | DELIVERY OF ABETA VARIANTS FOR AGGREGATION INHIBITION | Final Rejection | Baylor College of Medicine |
| 18562806 | METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS | Non-Final OA | THE U.S.A., as represented by the Secretary, Department of Health and Human Services |
| 18488859 | TREATMENT OF CANAVAN DISEASE | Final Rejection | CITY OF HOPE |
| 17833506 | METHOD FOR CULTURING MYOGENIC CELLS, CULTURES OBTAINED THEREFROM, SCREENING METHODS, AND CELL CULTURE MEDIUM | Final Rejection | Erasmus University Medical Center Rotterdam |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy